// App-Quantinova.ai

: Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD

Researchers

Presenter

  • Gary Ferguson

Principal Investigators

  • Krishna K. Pudi

  • Gregory Feldmann

  • Srikanth Pendyala

  • Chris N. Barnes

  • Edmund J. Moran

  • Glenn Crater

  • Brett Haumann

Medical Centers

  • Pulmonary Research Institute of Southeast Michigan, Farmingtin Hills, MI, United States.

  • Upstate Pharmaceutical Research, Greenville, SC, United States of America

  • S. Carolina Pharmaceutical Research, Spartanburg, SC, United States,

  • Theravance Biopharma US, Inc., South San Francisco, United States of America

  • Theravance Biopharma UK, Limited, London, United Kingdom,

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Revefenacin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • NCT02459080

  • NCT02512510

  • NCT02518139

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved